Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection

27 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...

Read more →

Pembrolizumab in combination with trastuzumab and chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma (final guidance)

12 June 2024 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with trastuzumab and ...

Read more →

Ivosidenib in combination with azacitidine for the first-line treatment of patients with IDH1 R132 mutation positive acute myeloid leukaemia (final guidance)

5 June 2024 - NICE has published final evidence-based guidance on the use of ivosidenib with azacitidine in the NHS ...

Read more →

Nivolumab for the adjuvant treatment of patients 12 years and older with completely resected melanoma at high risk of recurrence

5 June 2024 - NICE is unable to make a recommendation on the use of nivolumab (Opdivo) for the adjuvant treatment ...

Read more →

Zanubrutinib in combination with obinutuzumab for the treatment of patients with relapsed or refractory B-cell follicular lymphoma after two or more treatments

28 May 2024 - NICE is unable to make a recommendation on the use of zanubrutinib (Brukinsa) in combination with obinutuzumab ...

Read more →

Dabrafenib mesylate in combination with trametinib dimethyl sulphoxide for the treatment of children and adolescents with BRAF V600E mutation positive glioma

29 May 2024 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Finlee) in combination with ...

Read more →

Tisagenlecleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia

15 May 2024 - NICE has published final evidence-based recommendations on the use of tisagenlecleucel (Kymriah) for the treatment of ...

Read more →

Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (final guidance)

15 May 2024 - NICE has published final evidence-based recommendations on the use of selinexor (Nexpovio) in combination with bortezomib ...

Read more →

Tests could lead to fewer people having unnecessary chemotherapy after surgery for early breast cancer

10 May 2024 - More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with RET alterations that has not been treated with systemic therapy

1 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Pembrolizumab for the treatment of patients 3 years and older with relapsed or refractory classical Hodgkin's lymphoma

1 May 2024 - NICE has published updated evidence-based recommendations on the pembrolizumab (Keytruda) for the treatment of patients with ...

Read more →

Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma

25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination ...

Read more →

Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment

24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...

Read more →

Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer

24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin ...

Read more →

Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS

11 April 2024 - Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia. ...

Read more →